Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 289

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma

Open access
Touzeau, C, Dousset, C, Le Gouill, S, Sampath, D, Leverson, J D, Souers, A J, Maïga, S, Béné, M C, Moreau, P, Pellat-Deceunynck, C, Amiot, M · 2014 · Leukemia

Abstract

Despite recent advances in the treatment of multiple myeloma (MM), including proteasome inhibitors and immunomodulatory agents, patients invariably relapse and alternative treatment strategies are urgently needed. Bcl-2 inhibitors such as ABT-737 and ABT-263 (navitoclax), which target specifically anti-apoptotic proteins Bcl-2 and Bcl-x L , bring new hope for therapy. 1 We recently demonstrated that ABT-737 induces apoptotic cell death in a sub-group of MM at low nanomolar concentration (<150 n M ). 2 This sub-group of MM can be identified by its high Bcl-2/Mcl-1 Affymetrix gene expression ratio indicating that the expression level of Bcl-2 versus Mcl-1 mainly determines the susceptibility of myeloma cells to ABT-737 as previously demonstrated in other hematopoietic cells. 3 In addition, we have shown that Mcl-1 silencing strongly increases the sensitivity to ABT-737 of MM cells, highlighting the essential role of Mcl-1 in ABT-737 resistance. Although the orally active navitoclax has entered clinical trials and shown activity in hematological malignancies that are believed to be Bcl-2 dependent, the efficacy of this agent is limited by the thrombocytopenia caused by Bcl-x L inhibition. 4 To overcome this dose-limiting toxicity, ABT-199, the first-in-class orally bioavailable Bcl-2-selective BH3 mimetic, has been developed. Notably, it was reported that selective inhibition of Bcl-2 by ABT-199 demonstrated weak activity ex vivo on platelets. 5 These data were further extended to clinical observations. Indeed, ABT-199 showed promising antitumor activity while sparing platelets in chronic lymphoid leukemia patients. 5 Moreover, in a mouse model, ABT-199 also demonstrated in vivo efficacy against aggressive lymphoma without provoking thrombocytopenia. 6

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/leu.2013.216

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 289

Metadata

Authors
Touzeau, C., Dousset, C., Le Gouill, S., Sampath, D., Leverson, J. D., Souers, A. J., Maïga, S., Béné, M. C., Moreau, P., Pellat-Deceunynck, C., & Amiot, M.
Venue
Leukemia
Published
2013-07-17
Volume
28
Issue
1
Pages
210-212
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W2050702798
Cited by
289
References
10
FWCI
13.01
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. https://app.cochat.ai/papers/10.1038/leu.2013.216
The paper
Touzeau, C., Dousset, C., Le Gouill, S., Sampath, D., Leverson, J. D., Souers, A. J., Maïga, S., Béné, M. C., Moreau, P., Pellat-Deceunynck, C., & Amiot, M. (2014). The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia. https://doi.org/10.1038/leu.2013.216

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.